Investigator-Initiated Studies Main Article
Investigator-Initiated Studies
Daiichi Sankyo is committed to supporting research to address unmet medical needs of patients around the world.
Daiichi Sankyo offers the opportunity for external researchers who are interested in conducting their own research related to Daiichi Sankyo therapeutic areas of interest to submit an independent research concept that is subsequently reviewed by an internal review committee. Daiichi Sankyo may provide funding and other forms of support, such as clinical trial material, to support studies initiated and sponsored by external researchers.
If you would like to read about our current therapeutic areas of focus click Product Pipeline. If you are interested in submitting a concept, or have a question, please review the Investigator-Initiated Study (IIS) Reference Guide and submit your concept to https://daiichisankyo-iis.com/.
When you are ready, please submit your concept to:
If you are interested in submitting a concept related to trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki in the United States only), please review the Areas of Interest prior to making your submission.
Please note for all submissions:
- Concepts will be prioritized accordingly based on scientific merit and fit with the clinical program.
HER2+ mBC |
|
---|---|
HER2 Low mBC |
|
HER2+ mGC |
|
HER2 Targetable NSCLC |
|